Published in Hugo J on January 30, 2011
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol (2014) 2.23
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res (2012) 2.07
Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res (2013) 1.10
Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem (2014) 1.08
Correlation of LINE-1 methylation levels in patient-matched buffy coat, serum, buccal cell, and bladder tumor tissue DNA samples. Cancer Epidemiol Biomarkers Prev (2012) 0.94
Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol (2012) 0.90
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC). PLoS One (2016) 0.85
Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma. Cancer Med (2013) 0.84
Identification of Predictive Early Biomarkers for Sterile-SIRS after Cardiovascular Surgery. PLoS One (2015) 0.79
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. Oncologist (2016) 0.79
Multiplex Preamplification of Serum DNA to Facilitate Reliable Detection of Extremely Rare Cancer Mutations in Circulating DNA by Digital PCR. J Mol Diagn (2016) 0.78
Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Transl Lung Cancer Res (2016) 0.78
Mutational analysis of cytocentrifugation supernatant fluid from pancreatic solid mass lesions. Diagn Cytopathol (2013) 0.76
Detection of BRAF mutation in the cytocentrifugation supernatant fluid from fine-needle aspiration of thyroid lesions may enhance the diagnostic yield. Cytojournal (2017) 0.75
The added value of using mutational profiling in addition to cytology in diagnosing aggressive pancreaticobiliary disease: review of clinical cases at a single center. BMC Gastroenterol (2014) 0.75
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
The cancer genome. Nature (2009) 23.13
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 13.47
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2008) 9.98
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Prevalence of ras gene mutations in human colorectal cancers. Nature (1987) 9.23
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res (2004) 7.76
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res (2008) 6.91
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol (2006) 6.55
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature (1991) 6.16
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
p53 and human cancer: the first ten thousand mutations. Adv Cancer Res (2000) 4.71
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 4.59
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods (2006) 4.21
Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res (2005) 4.14
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene (2005) 4.07
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res (2006) 3.66
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res (2006) 3.55
Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res (2009) 3.41
[Not Available]. C R Seances Soc Biol Fil (1948) 3.32
Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn (2010) 3.12
BEAMing up for detection and quantification of rare sequence variants. Nat Methods (2006) 3.03
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2008) 2.75
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene (2007) 2.71
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res (2009) 2.35
About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta (2001) 2.18
Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology (1989) 2.03
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer (2007) 2.00
Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat (2010) 1.96
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol (2008) 1.93
Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J Clin Invest (1990) 1.93
The origin and mechanism of circulating DNA. Ann N Y Acad Sci (2000) 1.87
Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett (2003) 1.60
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat (2010) 1.59
K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol (1999) 1.53
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer (2009) 1.50
249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene (2005) 1.49
Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res (2004) 1.47
Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol (1987) 1.37
Multiplexed assays for detection of mutations in PIK3CA. Clin Chem (2008) 1.36
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res (2007) 1.33
Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res (2010) 1.23
Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn (2007) 1.18
KRAS mutation testing in colorectal cancer. Adv Anat Pathol (2009) 1.17
Toward noninvasive genomic screening of lung cancer patients. J Clin Oncol (2009) 1.07
Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer (2007) 1.06
Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg (2004) 1.05
Pathology of the hereditary colorectal carcinoma. Fam Cancer (2007) 1.04
A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas (2002) 1.00
Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer (2004) 0.98
Circulating tumour-derived predictive biomarkers in oncology. Drug Discov Today (2010) 0.95
Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer. PLoS One (2009) 0.94
Targets of oncogenes and tumor suppressors: key for understanding basic mechanisms of carcinogenesis. Biochemistry (Mosc) (2000) 0.92
Cell-free DNA resuscitated for tumor testing. Nat Med (2008) 0.92
Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients. Clin Chim Acta (2010) 0.83
Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck (2010) 0.81
Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases. Cancer Lett (2008) 0.81
Characterisation of circulating DNA by parallel tagged sequencing on the 454 platform. Clin Chim Acta (2009) 0.80
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37
Experimental annotation of the human genome using microarray technology. Nature (2001) 10.39
Circulating adhesion molecules in disease. Immunol Today (1993) 6.22
CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature (1997) 5.45
CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med (1997) 5.18
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J (1993) 3.75
Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest (1996) 3.74
Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature (1991) 3.61
Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res (2001) 3.45
Activation-independent binding of human memory T cells to adhesion molecule ELAM-1. Nature (1991) 3.45
Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med (1996) 3.33
Lymphocyte interactions with endothelial cells. Immunol Today (1992) 3.31
Histochemical Studies on Tissue Enzymes: III. A Study of the Distribution of Acid Phosphatases with Special Reference to the Nervous System. Am J Pathol (1943) 3.31
Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol (1997) 3.24
Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol (1999) 3.18
Introduction--the validity of self-reported drug use: improving the accuracy of survey estimates. NIDA Res Monogr (1997) 3.09
The relevance of drug injectors' social and risk networks for understanding and preventing HIV infection. Soc Sci Med (1994) 3.05
IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol (1992) 2.89
The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem (1998) 2.88
Blind and partial sight registration in Avon. Br J Ophthalmol (1989) 2.88
Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med (1991) 2.76
Assessing the comprehension and production of language in young children: an account of the Reynell Developmental Language Scales III. Int J Lang Commun Disord (2004) 2.70
Early neutering of dogs. Vet Rec (2000) 2.60
IgA subclasses in various secretions and in serum. Immunology (1982) 2.43
Low back pain. J R Coll Gen Pract (1968) 2.39
CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion. J Exp Med (1992) 2.38
A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature (1995) 2.29
Four molecular pathways of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1, and ELAM-1 and changes in pathway hierarchy under different activation conditions. J Cell Biol (1991) 2.27
Perceptions and reactions of the public to diarrhoea. J R Soc Health (1993) 2.22
Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Circulation (1998) 2.21
A multidisciplinary audit of clinical coding accuracy in otolaryngology: financial, managerial and clinical governance considerations under payment-by-results. Clin Otolaryngol (2009) 2.20
Care of the suddenly bereaved. BMJ (1990) 2.19
Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50. J Immunol (1983) 2.13
Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol (1994) 2.11
Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000-2008. Anticancer Agents Med Chem (2009) 2.09
Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239. J Virol (1997) 2.04
T cells bind to cytokine-activated endothelial cells via a novel, inducible sialoglycoprotein and endothelial leukocyte adhesion molecule-1. J Immunol (1990) 2.00
The RAD50 gene, a member of the double strand break repair epistasis group, is not required for spontaneous mitotic recombination in yeast. Curr Genet (1990) 1.93
Changes in size, subclass, and metabolic properties of serum immunoglobulin A in liver diseases and in other diseases with high serum immunoglobulin A. J Clin Invest (1983) 1.86
Selective transport of polymeric immunoglobulin A in bile. Quantitative relationships of monomeric and polymeric immunoglobulin A, immunoglobulin M, and other proteins in serum, bile, and saliva. J Clin Invest (1982) 1.84
'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. J Immunol Methods (2009) 1.81
Requirement of basement membrane for the suppression of programmed cell death in mammary epithelium. J Cell Sci (1996) 1.80
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78
Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst (2000) 1.77
A schematic eye for the rat. Vision Res (1979) 1.77
Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology (1996) 1.74
Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol (1997) 1.72
Interleukin 2 induces gamma-interferon production: participation of macrophages and NK-like cells. J Immunol (1983) 1.72
Multiple neurological abnormalities in mice deficient in the G protein Go. Proc Natl Acad Sci U S A (1998) 1.70
Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer. Clin Oncol (R Coll Radiol) (2005) 1.67
Chlamydia trachomatis detection and the menstrual cycle. Lancet (1998) 1.63
An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol (2012) 1.63
Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol (1997) 1.62
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol (2003) 1.62
Nature and origin of the proteins of bile. I. A comparative analysis of serum and bile proteins in man. Eur J Clin Invest (1974) 1.59
Review of biomarkers in colorectal cancer. Colorectal Dis (2012) 1.59
bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res (1993) 1.59
Sleep benefit in Parkinson's disease. Mov Disord (1997) 1.56
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer (2009) 1.50
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer (2011) 1.50
Apoptosis and cancer chemotherapy. Trends Cell Biol (2001) 1.48
Topographical relationships between the anatomy and physiology of the rabbit visual system. Doc Ophthalmol (1971) 1.47
Insecticide resistance monitoring of field-collected Anopheles gambiae s.l. populations from Jinja, eastern Uganda, identifies high levels of pyrethroid resistance. Med Vet Entomol (2012) 1.46
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer (2004) 1.45
Secretion of immunoglobulins and plasma proteins from the jejunal mucosa. Transport rate and origin of polymeric immunoglobulin A. J Clin Invest (1984) 1.44
Primary renal hypoplasia in humans and mice with PAX2 mutations: evidence of increased apoptosis in fetal kidneys of Pax2(1Neu) +/- mutant mice. Hum Mol Genet (2000) 1.44
Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes. Invest Ophthalmol Vis Sci (1991) 1.44
Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J Pharm Biomed Anal (2004) 1.44
Discrete steps in binding and signaling of interleukin-8 with its receptor. J Biol Chem (1996) 1.42
The structure of normal human attention: The Test of Everyday Attention. J Int Neuropsychol Soc (1996) 1.42
Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther (2007) 1.42
Biomarker method validation in anticancer drug development. Br J Pharmacol (2007) 1.41
Transport of animals. Vet Rec (1995) 1.39
Identification and control of nosocomial adenovirus keratoconjunctivitis in an ophthalmic department. Br J Ophthalmol (2008) 1.39
Wildlife rehabilitation. Vet Rec (1996) 1.39
Celiprolol. Lancet (1992) 1.38
Mobility impairments and use of preventive services in women with multiple sclerosis: observational study. BMJ (2001) 1.38
Origin and nature of the proteins of bile. II. A comparative analysis of serum, hepatic lymph and bile proteins in the dog. Eur J Clin Invest (1974) 1.38
Interaction between echovirus 7 and its receptor, decay-accelerating factor (CD55): evidence for a secondary cellular factor in A-particle formation. J Virol (1997) 1.38
Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer (2005) 1.36
Fetal heart rate and acid-base status in the assessment of fetal hypoxia. Am J Obstet Gynecol (1967) 1.35
Expression of VCAM-1 and E-selectin in an in vivo model of endothelial activation. Am J Pathol (1993) 1.35
Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci (1990) 1.34
Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. J Virol (1995) 1.34
Evidence for T cell nature and heterogeneity within natural killer (NK) and antibody-dependent cellular cytotoxicity (ADCC) effectors: a comparison with cytolytic T lymphocytes (CTL). J Immunol (1981) 1.33
Salicylates, platelets and adenine nucleotides. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 1.32
Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol (2008) 1.32
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol (2001) 1.32